PFE
ChallengerPfizer
$27.34
+1.60%
as of 13 Apr
Power Core
Pfizer's moat is its global manufacturing and commercialization infrastructure, which allows it to scale novel therapeutics from approval to multi-billion-dollar revenue faster than nearly any competitor.
Direction of Movement
Lateral With Downward Pressure From Multiple Vectors
ROC 200
+16.1%
PFE
Pfizer
$27.34
+1.60%
as of 13 Apr
DCF Fair Value: $39.09
Market data unavailable
Company Profile
Pfizer Inc. is a research-based global biopharmaceutical company founded in 1849 and headquartered in New York. It focuses on the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products worldwide, targeting developed and emerging markets to advance wellness, prevention, treatments, and cures for the most feared diseases. Operating in the health technology sector, specifically pharmaceuticals: major, Pfizer Inc. addresses critical areas such as oncology, rare diseases, internal medicine, inflammation and immunology, vaccines, anti-infectives, gene therapy, medicinal sciences, and precision medicine. Notable advancements include acquisitions like Global Blood Therapeutics in 2023 to bolster its biopharmaceutical portfolio, alongside recent clinical trial successes in prostate cancer, lung cancer, and bladder cancer therapies. With approximately 81,000 employees, Pfizer Inc. generates substantial revenue, reported at $63.63 billion for the fiscal year, and maintains a significant presence in the global market through innovative pipelines and partnerships.